Atlas Trials

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Clinical trial NCT04978584 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04978584
Sponsor
M.D. Anderson Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B-Cell Lymphoma
Start date
2022-03-03
Primary completion
2027-01-16
Enrollment
62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.